Name,CAS,Conc,Effecti,AC10µM,pi,Endpoint(s)
Tetrabutylammonium bromide,1643-19-2,5.44E-06,9.30E-06,5.850630427,9.60E-05,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
1-Hexyl-3-methylimidazolium bromide,85100-78-3,0,0,1.78268148,0,TOX21_AR_BLA_Antagonist_viability|TOX21_CAR_Agonist_viabillity|TOX21_CAR_Antagonist_viability|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
1-Benzylquinolinium chloride,15619-48-4,1.11E-07,1.00E-06,1.105812573,1.96E-06,NVS_GPCR_gMPeripheral_NonSelective|NVS_GPCR_gOpiateK|NVS_GPCR_hM2|NVS_GPCR_hM4|NVS_GPCR_hM5|NVS_GPCR_rAdra1A|NVS_GPCR_rmAdra2B|NVS_IC_rNaCh_site2|NVS_TR_gDAT|NVS_TR_hDAT
"1,1-Dimethylpiperidinium chloride",24307-26-4,2.44E-06,1.69E-05,1.447630182,4.31E-05,NVS_LGIC_rNNR_BungSens
1-Benzyl-3-methylimidazolium chloride,36443-80-8,3.33E-07,3.63E-07,9.167265169,5.88E-06,TOX21_RT_HEK293_GLO_40hr_viability
Methylene blue,61-73-4,2.22E-07,7.01E-06,0.316630152,3.92E-06,TOX21_MMP_rhodamine
Estrone,53-16-7,6.44E-06,4.44E-05,1.449160545,0.000113592,BSK_hDFCGF_Proliferation_down|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Stilonium iodide,77257-42-2,6.66E-07,1.95E-06,3.413901219,1.18E-05,TOX21_AR_BLA_Antagonist_viability|TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability
"1-Butyl-2,3-dimethylimidazolium iodide",108203-70-9,3.49E-05,0.000100737,3.461405541,0.000614965,TOX21_RT_HEPG2_GLO_40hr_viability
Imidacloprid,138261-41-3,1.11E-07,2.30E-06,0.481811238,1.96E-06,NVS_LGIC_hNNR_NBungSens|#SiNS|SH-S5Y5 neurite outgrowth
"1,3-Dinitrobenzene",99-65-0,1.33E-05,0.000624072,0.213528586,0.000235019,NVS_ENZ_rMAOAC|NVS_ENZ_rMAOAP|NVS_ENZ_rMAOBC|NVS_ENZ_rMAOBP
4-Nitropyridine-1-oxide,1124-33-0,2.61E-05,2.65E-05,9.841984056,0.000460245,TOX21_CASP3_CHO_viability|TOX21_ERb_BLA_Agonist_viability
"1,4-Dinitrobenzene",100-25-4,0.00018967,0.000213238,8.894755112,0.003345097,BSK_3C_Proliferation_down|BSK_SAg_Proliferation_down|BSK_hDFCGF_Proliferation_down|TOX21_CASP3_CHO_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_PXR_viability
"1-Fluoro-2,4-dinitrobenzene",70-34-8,2.50E-05,0.000722823,0.345668907,0.00044066,TOX21_MMP_ratio_down
"1,8-Dinitronaphthalene",602-38-0,2.78E-05,0.000134033,2.07127786,0.000489622,TOX21_MMP_rhodamine
1-Methyl-3-hexylimidazolium trifluoromethylsulfonate,460345-16-8,0,0,3.955792954,0,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_CAR_Agonist_viabillity|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Brolamfetamine hydrobromide,53581-53-6,1.11E-07,2.42E-07,4.581034558,1.96E-06,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_TR_LUC_GH3_Antagonist_viability
Pentabromoethane,75-95-6,4.44E-06,2.97E-06,14.95194107,7.83E-05,TOX21_HRE_BLA_Agonist_viability
"2,2',4,4',5-Pentabromodiphenyl ether",60348-60-9,0.000405546,0.007649427,0.530165724,0.007152398,TOX21_MMP_fitc
"4,4'-Dibromodiphenyl ether",2050-47-7,3.44E-05,0.00012341,2.789455379,0.000607131,TOX21_MMP_fitc
"1,2,5,6,9,10-Hexabromocyclododecane",3194-55-6,0.002165431,0.00375783,5.762451059,0.038190514,TOX21_CASP3_CHO_viability|TOX21_ERb_BLA_Agonist_viability|TOX21_PR_BLA_Agonist_viability|TOX21_PR_BLA_Antagonist_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_RXR_BLA_Agonist_viability|TOX21_p53_BLA_p2_viability|TOX21_p53_BLA_p3_viability
"1,2-Dibromo-2,4-dicyanobutane",35691-65-7,2.11E-06,9.97E-06,2.116272395,3.72E-05,NVS_GPCR_hDRD1|NVS_GPCR_hORL1|NVS_TR_gDAT
"1,2-Dibromo-4-(1,2-dibromoethyl)cyclohexane",3322-93-8,2.05E-05,2.71E-05,7.570879236,0.00036232,TOX21_MMP_ratio_down
4-(Diglycidylamino)phenyl glycidyl ether,5026-74-4,0,0,7.620650531,0,TOX21_PXR_viability|TOX21_RT_HEK293_GLO_40hr_viability
Cantharidin,56-25-7,1.11E-07,3.38E-05,0.032846803,1.96E-06,TOX21_MMP_ratio_down|TOX21_MMP_rhodamine
"2E,4E-Hexadienoic acid",110-44-1,0.000200552,0.000257578,7.786076862,0.003537029,APR_HepG2_MitoMass_72h_up
"(2,4,6-Trioxo-1,3,5-triazinane-1,3,5-triyl)triethane-2,1-diyl trisprop-2-enoate",40220-08-4,0,0,5.555487619,0,ATG_XTT_Cytotoxicity_up|TOX21_AR_BLA_Antagonist_viability|TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_AhR_LUC_Agonist_viability|TOX21_CAR_Agonist_viabillity|TOX21_CASP3_CHO_viability|TOX21_ELG1_LUC_Agonist_viability|TOX21_ERR_viability|TOX21_ERb_BLA_Agonist_viability|TOX21_FXR_BLA_antagonist_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PPARg_BLA_antagonist_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability
Diethylene glycol diacrylate,4074-88-8,0,0,20.31848309,0,TOX21_CASP3_CHO_viability|TOX21_ERR_viability|TOX21_PGC_ERR_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability
Diallyl phthalate,131-17-9,9.28E-05,0.000319143,2.908910408,0.001637296,NUMBER_OF_BURSTS|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|AREA_UNDER_CROSS_CORRELATION|SYNCHRONY_INDEX
"5,6,7,8-Tetrahydroquinoxaline",34413-35-9,3.31E-05,8.36E-05,3.957730737,0.000583629,TOX21_RT_HEPG2_FLO_00hr_ctrl_viability|TOX21_RT_HEPG2_FLO_24hr_viability
Mepanipyrim,110235-47-7,1.78E-06,2.54E-05,0.700036114,3.13E-05,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
3-Methylbut-3-en-1-ol,763-32-6,0.000346802,0.000111064,31.22547331,0.006116358,TOX21_RT_HEPG2_GLO_00hr_ctrl_viability
Diacetone alcohol,123-42-2,0.000648741,0.011018757,0.588760555,0.011441486,APR_HepG2_MitoMass_24h_dn
N-Acetyl-m-toluidine,537-92-8,2.22E-07,2.01E-07,11.05804855,3.92E-06,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
5-Nitro-2-furanmethanediol diacetate,92-55-7,3.09E-05,2.46E-05,12.53414464,0.00054446,TOX21_Aromatase_Inhibition_viability
Adefovir dipivoxil,142340-99-6,0,0,0.414304279,0,TOX21_CAR_Agonist_viabillity|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RXR_BLA_Agonist_viability
Triadimenol,55219-65-3,1.89E-06,0.001401329,0.013471586,3.33E-05,NVS_TR_gDAT|NVS_TR_hDAT
"2,6-Di-tert-butylphenol",128-39-2,2.65E-05,8.78E-06,30.21235672,0.000468079,APR_HepG2_CellLoss_24h_dn|NCCT_HEK293T_CellTiterGLO
"4,4'-(Isopropylidenebis(4,1-phenyleneoxy))dianiline",13080-86-9,1.67E-05,2.43E-05,6.865532673,0.000293773,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
2-Chloro-2-nitropropane,594-71-8,4.89E-06,0.000180945,0.270032179,8.62E-05,TOX21_RT_HEPG2_GLO_00hr_ctrl_viability
Hydroxyflutamide,52806-53-8,2.61E-05,0.001885569,0.138399698,0.000460245,APR_HepG2_MitoMass_72h_up|APR_HepG2_MitoMembPot_72h_dn|TOX21_MMP_ratio_down
Esfenvalerate,66230-04-4,0.000225649,0.02723309,0.082858401,0.003979647,NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Isopropamide,7492-32-2,7.77E-07,2.15E-06,3.608828296,1.37E-05,TOX21_RT_HEPG2_GLO_40hr_viability
Allethrin,584-79-2,1.89E-06,2.19E-05,0.86320574,3.33E-05,INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|SYNCHRONY_INDEX
Riboprine,7724-76-7,6.66E-07,4.49E-06,1.483109697,1.18E-05,TOX21_ARE_BLA_agonist_viability|TOX21_CAR_Agonist_viabillity|TOX21_CAR_Antagonist_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_NFkB_BLA_agonist_viability|TOX21_PPARg_BLA_antagonist_viability|TOX21_PXR_viability|TOX21_RORg_LUC_CHO_Antagonist_viability
"2,2,4-Trimethyl-1,3-pentanediol",144-19-4,2.55E-06,6.41E-05,0.398237968,4.50E-05,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_GLO_16hr_ctrl_viability
Imazapyr,81334-34-1,1.31E-05,0.044585776,0.002938972,0.000231102,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|BURST_DURATION_AVG_ (SEC)|INTER_BURST_INTERVAL_AVG_(SEC)|NETWORK_BURST_PERCENTAGE|SYNCHRONY_INDEX
Deethylatrazine,6190-65-4,1.48E-05,0.03310085,0.004461925,0.000260479,SH-S5Y5 neurite outgrowth
Oxadiazon,19666-30-9,1.01E-05,0.006993013,0.014450631,0.000178222,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|BURST_PERCENTAGE_AVG_(SEC)|NETWORK_BURST_PERCENTAGE
Bicalutamide,90357-06-5,2.30E-05,0.138139385,0.001664035,0.000405407,SH-S5Y5 viability
"2-Methyl-2,4-pentanediol",107-41-5,0.000792437,0.000548482,14.44782648,0.01397577,APR_HepG2_CellLoss_72h_dn|BSK_3C_Proliferation_down|BSK_hDFCGF_Proliferation_down
trans-Hex-3-en-1-ol,928-97-2,5.55E-07,9.91E-07,5.602680159,9.79E-06,TOX21_PR_BLA_Agonist_viability
Clomazone,81777-89-1,0,0,0.048878912,0,NVS_TR_hDAT|SH-S5Y5 neurite outgrowth
"5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin",63612-50-0,2.29E-05,5.73E-05,3.990582101,0.000403449,NCCT_MITO_max_resp_rate_OCR_dn|NVS_GPCR_bAdoR_NonSelective
"2,3-Dimethylphenol",526-75-0,0,0,0.149726139,0,ACEA_AR_antagonist_AUC_viability|TOX21_RT_HEK293_FLO_08hr_viability
Terbacil,5902-51-2,0,0,0.887543958,0,BSK_SAg_PBMCCytotoxicity_up
4-Chloro-3-methylphenol,59-50-7,1.89E-06,0.003163896,0.005966731,3.33E-05,SH-S5Y5 viability
Rimonabant,168273-06-1,2.34E-05,0.000793232,0.295387389,0.000413241,TOX21_RT_HEK293_GLO_40hr_viability
2-Amino-m-cresol,2835-97-4,3.33E-07,1.70E-08,196.0749469,5.88E-06,TOX21_RT_HEK293_GLO_40hr_viability
"4,4'-Diamino-3,3'-dimethyldiphenylmethane",838-88-0,4.44E-07,1.31E-06,3.384765538,7.83E-06,APR_HepG2_MitoMass_72h_up|NCCT_MITO_basal_resp_rate_OCR_dn|NVS_TR_hDAT|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NETWORK_BURST_PERCENTAGE|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
4-Chloro-2-methylaniline,95-69-2,3.33E-07,9.07E-06,0.367288361,5.88E-06,ACEA_ER_AUC_viability|BSK_3C_Proliferation_down
Methylhydroquinone,95-71-6,1.11E-07,7.10E-08,15.63149714,1.96E-06,TOX21_RXR_BLA_Agonist_viability|TOX21_SSH_3T3_GLI3_Agonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
"2-Methyl-1,3-benzenediol",608-25-3,2.22E-07,5.70E-06,0.38989635,3.92E-06,BSK_SAg_PBMCCytotoxicity_down|BSK_SAg_Proliferation_down
Tiliquinol,5541-67-3,0,0,2.135862637,0,TOX21_AR_BLA_Antagonist_viability|TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability|TOX21_CAR_Agonist_viabillity|TOX21_CAR_Antagonist_viability|TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PR_BLA_Antagonist_viability|TOX21_RORg_LUC_CHO_Antagonist_viability|TOX21_VDR_BLA_Agonist_viability
2-Methyl-4-nitroaniline,99-52-5,0,0,16.19358673,0,TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability|TOX21_CAR_Antagonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
"3,3'-Dimethylbenzidine",119-93-7,0.000310045,0.00215133,1.44117971,0.005468098,ACEA_AR_antagonist_AUC_viability|BSK_SAg_Proliferation_down
Isophorone,78-59-1,2.33E-06,0.00891102,0.002616988,4.11E-05,TOX21_RT_HEPG2_FLO_32hr_ctrl_viability
"3,5-Dimethylpyridine",591-22-0,4.19E-05,0.00046333,0.903567086,0.00073835,ACEA_ER_AUC_viability
4-Methylcatechol,452-86-8,1.11E-07,5.60E-08,19.83385772,1.96E-06,TOX21_SSH_3T3_GLI3_Agonist_viability
"3,4-Dinitrotoluene",610-39-9,2.67E-05,0.000204455,1.303537957,0.000470037,NVS_ENZ_rMAOAC
Diiodomethyl 4-methylphenyl sulfone,20018-09-1,8.22E-06,0.000187009,0.43941901,0.000144928,NVS_GPCR_hDRD1|NVS_TR_rVMAT2
"3,4-Diaminotoluene",496-72-0,1.44E-06,1.38E-05,1.049892479,2.55E-05,INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|SYNCHRONY_INDEX
C.I. Solvent Orange 7,3118-97-6,1.92E-05,0.000116512,1.6488666,0.000338818,BSK_SAg_Proliferation_down|TOX21_CASP3_CHO_viability|TOX21_PXR_viability
1-Phenyl-3-methyl-5-pyrazolone,89-25-8,6.66E-07,9.78E-07,6.810060088,1.18E-05,TOX21_MMP_rhodamine
"2,2-Dichloro-1-(3-methyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethanone",98730-04-2,0,0,3.141276752,0,ACEA_AR_agonist_AUC_viability|ACEA_ER_AUC_viability|BSK_3C_Proliferation_down|BSK_3C_Vis_down|BSK_CASM3C_Proliferation_down|BSK_CASM3C_SRB_down|BSK_SAg_SRB_down|BSK_hDFCGF_Proliferation_down|BSK_hDFCGF_SRB_down|TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_Aromatase_Inhibition_viability|TOX21_CASP3_CHO_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
Flopropione,2295-58-1,0,0,2.015497245,0,TOX21_MMP_ratio_down
Iopanoic acid,96-83-3,2.22E-05,0.000709177,0.313173512,0.000391698,ACEA_AR_agonist_AUC_viability
2-Ethylphenol,90-00-6,0,0,2.906933037,0,TOX21_RT_HEK293_FLO_40hr_viability
"2,2'-Methylenebis(ethyl-6-tert-butylphenol)",88-24-4,0.005671208,0.145481894,0.389822289,0.100019977,TOX21_MMP_rhodamine
Enefexine,67765-04-2,6.66E-07,2.18E-06,3.053176619,1.18E-05,TOX21_PR_BLA_Agonist_viability
Imazethapyr,81335-77-5,2.22E-07,0.000179461,0.012375674,3.92E-06,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|AREA_UNDER_CROSS_CORRELATION
Pyrimethamine,58-14-0,0,0,0.404722448,0,NVS_GPCR_hAdra2A|NVS_GPCR_hDRD1|NVS_GPCR_rAdra1A|NVS_GPCR_rAdra1B|NVS_GPCR_rAdra1_NonSelective|NVS_GPCR_rAdra2_NonSelective|NVS_GPCR_rmAdra2B|NVS_IC_rCaBTZCHL|NVS_IC_rNaCh_site2|NVS_TR_gDAT|NVS_TR_hDAT|NVS_TR_hNET|NVS_GPCR_g5HT4|NVS_GPCR_h5HT2A|NVS_GPCR_h5HT7|NVS_GPCR_p5HT2C
Valproic acid,99-66-1,2.22E-07,2.89E-08,76.93555562,3.92E-06,%SiNS|NSDsd|#SiNS
6-Propyl-2-thiouracil,51-52-5,1.89E-06,0.001881889,0.010031472,3.33E-05,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|AREA_UNDER_CROSS_CORRELATION
MEHP,4376-20-9,1.95E-05,0.000313321,0.623781901,0.000344694,NCCT_MITO_basal_resp_rate_OCR_dn
gamma-Decanolactone,706-14-9,2.22E-07,2.20E-06,1.007543638,3.92E-06,ACEA_AR_antagonist_AUC_viability
5-Heptyldihydro-2(3H)-furanone,104-67-6,5.55E-07,2.43E-06,2.288031992,9.79E-06,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|AREA_UNDER_CROSS_CORRELATION
Carmofur,61422-45-5,1.11E-07,4.58E-07,2.426424499,1.96E-06,TOX21_ERb_BLA_Agonist_viability
N-Butylbenzenesulfonamide,3622-84-2,0.007378012,0.074557292,0.989576227,0.130121935,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
2-Butoxyethanol,111-76-2,0.001118251,0.129894887,0.086088902,0.019721973,SH-S5Y5 neurite outgrowth
"3,6,9,12-Tetraoxahexadecan-1-ol",1559-34-8,1.11E-06,2.27E-06,4.894391329,1.96E-05,TOX21_PR_BLA_Antagonist_viability
Dibutyl butylphosphonate,78-46-6,0.000512485,0.0003628,14.12581818,0.009038422,TOX21_RT_HEPG2_GLO_00hr_ctrl_viability
Tributyl phosphate,126-73-8,0.00625643,0.02999274,2.085981529,0.110341208,NCCT_MITO_basal_resp_rate_OCR_dn|NCCT_MITO_max_resp_rate_OCR_dn|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|INTER_BURST_INTERVAL_AVG_(SEC)|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION
Propylparaben,94-13-3,0,0,0.713099043,0,NVS_GPCR_hAdoRA1|NVS_TR_hDAT
Oxibendazole,20559-55-1,0,0,0.087831341,0,TOX21_PGC_ERR_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
Albendazole oxide,54029-12-8,1.11E-07,4.90E-07,2.266039514,1.96E-06,TOX21_RT_HEK293_GLO_40hr_viability
4-(Diethylamino)salicylaldehyde,17754-90-4,0,0,5.332508599,0,TOX21_RXR_BLA_Agonist_viability
4-(Diethylamino)benzaldehyde,120-21-8,0,0,1.883556624,0,NVS_TR_rSERT
"N,N-Diethyl-p-phenylenediamine",93-05-0,1.11E-07,3.04E-07,3.655677995,1.96E-06,TOX21_AR_BLA_Antagonist_viability|TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_CAR_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_H2AX_HTRF_CHO_viability|TOX21_MMP_viability|TOX21_PR_BLA_Antagonist_viability|TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RXR_BLA_Agonist_viability|TOX21_SBE_BLA_Antagonist_viability|TOX21_SSH_3T3_GLI3_Agonist_viability|TOX21_VDR_BLA_Agonist_viability
"N-Ethyl-N-(3-methylphenyl)ethane-1,2-diamine",19248-13-6,3.44E-06,1.57E-06,21.94058905,6.07E-05,TOX21_RT_HEPG2_FLO_24hr_viability
Atrazine,1912-24-9,1.01E-05,5.43E-05,1.860940538,0.000178222,NVS_GPCR_bAdoR_NonSelective|NUMBER_OF_BURSTS|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX|SH-S5Y5 neurite outgrowth
N-Ethylperfluorooctanesulfonamide,4151-50-2,1.47E-05,1.17E-05,12.48951309,0.00025852,APR_HepG2_CellLoss_24h_dn|APR_HepG2_CellLoss_72h_dn|APR_HepG2_MicrotubuleCSK_24h_up|APR_HepG2_MicrotubuleCSK_72h_up|TOX21_ARE_BLA_agonist_viability
Ethyl 4-oxo-1-piperidinecarboxylate,29976-53-2,7.93E-05,0.004065352,0.195033774,0.00139836,TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
"Ethyl 4-(5-chloro-2,3-dihydro-2-oxo-1h-benzimidazol-2-yl)piperidine-1-carboxylate",53786-46-2,0,0,0.502248261,0,TOX21_CAR_Antagonist_viability|TOX21_RT_HEK293_GLO_08hr_viability
2-Ethoxyaniline,94-70-2,1.11E-07,1.04E-06,1.067746615,1.96E-06,TOX21_RT_HEK293_GLO_40hr_viability
2-Ethoxy-5-(1-propenyl)phenol,94-86-0,0,0,0.728521912,0,NVS_TR_hNET
Oxyfluorfen,42874-03-3,1.08E-05,5.26E-05,2.045989528,0.000189973,TOX21_MMP_rhodamine
4-Ethoxyphenol,622-62-8,0,0,8.589724428,0,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_24hr_viability
Tralkoxydim,87820-88-0,2.11E-06,4.84E-05,0.435844196,3.72E-05,NVS_GPCR_hAdra2A|NVS_GPCR_rmAdra2B
Ethyl 4-nitrophenyl ethylphosphonate,546-71-4,0,0,6.619520138,0,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability
Paraoxon,311-45-5,1.58E-05,0.085827554,0.001837263,0.000278105,SH-S5Y5 neurite outgrowth
Diazoxon,962-58-3,0,0,0.004671898,0,SH-S5Y5 neurite outgrowth
Ethyl dichlorophosphate,1498-51-7,3.10E-05,0.000569561,0.543968776,0.000546418,TOX21_RT_HEK293_GLO_32hr_viability
Molinate,2212-67-1,1.07E-05,0.000176724,0.603234692,0.000188015,NVS_GPCR_hM2
Mabuterol hydrochloride,54240-36-7,2.22E-07,9.77E-07,2.27241791,3.92E-06,TOX21_AhR_LUC_Agonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
Proguanil hydrochloride,637-32-1,1.11E-07,8.24E-07,1.34752925,1.96E-06,TOX21_CASP3_CHO_viability|TOX21_PPARd_BLA_antagonist_viability|TOX21_RT_HEPG2_FLO_16hr_ctrl_viability
2-Chloropropyldimethylamine hydrochloride,4584-49-0,9.77E-06,6.14E-06,15.90778721,0.000172347,BSK_SAg_PBMCCytotoxicity_down|BSK_SAg_Proliferation_down
Cycloguanil hydrochloride,152-53-4,3.30E-05,0.000199382,1.654171812,0.000581671,TOX21_p53_BLA_p2_viability|TOX21_p53_BLA_p4_viability
"(-)-2,5-Dimethoxy-4-ethylamphetamine hydrochloride",42011-76-7,2.22E-07,2.56E-07,8.674465516,3.92E-06,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability
"(+)-2,5-Dimethoxy-4-ethylamphetamine hydrochloride",50505-91-4,1.11E-07,2.19E-07,5.069391509,1.96E-06,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_TR_LUC_GH3_Antagonist_viability
Irinotecan hydrochloride,100286-90-6,0,0,1.403237547,0,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Benzidine dihydrochloride,531-85-1,0,0,4.137756951,0,TOX21_ERb_BLA_Agonist_viability
N-(1-Naphthyl)ethylenediamine dihydrochloride,1465-25-4,3.33E-07,4.13E-07,8.070027019,5.88E-06,TOX21_ERb_BLA_Antagonist_viability|TOX21_RT_HEK293_GLO_00hr_viability
Clonidine hydrochloride,4205-91-8,1.11E-07,4.56E-08,24.36514448,1.96E-06,TOX21_PR_BLA_Antagonist_viability
"1,3-Dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazoline hydrochloride (1:1)",149062-75-9,1.11E-07,4.63E-06,0.240015417,1.96E-06,NVS_ENZ_hAChE|NVS_ENZ_rAChE|NVS_ENZ_rMAOAC|NVS_ENZ_rMAOAP|NVS_GPCR_gMPeripheral_NonSelective|NVS_GPCR_hAdra2A|NVS_GPCR_hM1|NVS_GPCR_hM2|NVS_GPCR_hM3|NVS_GPCR_hM4|NVS_GPCR_hM5|NVS_GPCR_rAdra1A|NVS_GPCR_rAdra1_NonSelective|NVS_GPCR_rAdra2_NonSelective|NVS_GPCR_rOpiate_NonSelective|NVS_GPCR_rmAdra2B|NVS_LGIC_hNNR_NBungSens|NVS_LGIC_rNNR_BungSens|NVS_TR_hNET
Dexchlorpheniramine hydrochloride,5502-69-2,2.78E-06,5.61E-06,4.949850472,4.90E-05,TOX21_PXR_viability
Clomipramine hydrochloride,17321-77-6,6.44E-05,8.35E-05,7.71164725,0.001135923,ATG_XTT_Cytotoxicity_up|TOX21_ERb_BLA_Agonist_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PPARd_BLA_antagonist_viability|TOX21_TR_LUC_GH3_Antagonist_viability|TOX21_VDR_BLA_antagonist_viability
Diphenhydramine hydrochloride,147-24-0,0.000379117,0.006261187,0.605503384,0.006686278,NVS_ENZ_hES|NVS_GPCR_gMPeripheral_NonSelective|NVS_GPCR_gOpiateK|NVS_GPCR_hAdra2A|NVS_GPCR_hAdra2C|NVS_GPCR_hDRD1|NVS_GPCR_hM1|NVS_GPCR_hM2|NVS_GPCR_hM3|NVS_GPCR_hM4|NVS_GPCR_hM5|NVS_GPCR_rAdra1A|NVS_GPCR_rAdra1B|NVS_GPCR_rAdra1_NonSelective|NVS_GPCR_rAdra2_NonSelective|NVS_GPCR_rOpiate_NonSelective|NVS_GPCR_rmAdra2B|NVS_IC_rCaBTZCHL|NVS_IC_rNaCh_site2|NVS_TR_gDAT|NVS_TR_hDAT|NVS_TR_hNET|NVS_TR_rNET|NVS_GPCR_h5HT2A|NVS_GPCR_h5HT7|NVS_GPCR_p5HT2C|NVS_GPCR_r5HT_NonSelective|NVS_TR_rSERT|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Naftifine hydrochloride,65473-14-5,2.08E-05,0.000121159,1.713935663,0.000366237,TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RXR_BLA_Agonist_viability
"L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride",1421-65-4,7.77E-07,1.59E-06,4.894372072,1.37E-05,TOX21_Aromatase_Inhibition_viability
"R-(-)-2,5-Dimethoxy-4-bromoamphetamine hydrochloride",50505-92-5,1.11E-07,2.37E-07,4.679882271,1.96E-06,TOX21_ERb_BLA_Agonist_viability|TOX21_PR_BLA_Agonist_viability|TOX21_PXR_viability|TOX21_TR_LUC_GH3_Antagonist_viability
"S-(+)-2,5-Dimethoxy-4-bromoamphetamine hydrochloride",50505-93-6,1.11E-07,3.32E-07,3.348977947,1.96E-06,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability
"4-Bromo-2,5-dimethoxyamphetamine hydrochloride",29705-96-2,1.11E-07,2.08E-07,5.334027081,1.96E-06,TOX21_PXR_viability|TOX21_RT_HEK293_GLO_40hr_viability
p-Anisidinium chloride,20265-97-8,2.22E-07,3.19E-06,0.695527866,3.92E-06,ACEA_ER_AUC_viability|NCCT_HEK293T_CellTiterGLO
1-Phenylcyclohexylamine hydrochloride,1934-71-0,0,0,8.019889355,0,TOX21_SSH_3T3_GLI3_Agonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
4-Chloroaniline hydrochloride,20265-96-7,2.51E-05,0.000199442,1.258352712,0.000442618,ACEA_ER_AUC_viability
C.I. Basic Orange 2,532-82-1,0,0,0.864668742,0,TOX21_MMP_ratio_down
Lindane,58-89-9,0.000153024,0.000903684,1.693333333,0.002698796,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|BURST_DURATION_AVG_ (SEC)|NUMBER_OF_SPIKES_PER_BURST_AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|AREA_UNDER_CROSS_CORRELATION|MFR|BR|BD|IBI|#NS|NSDsd|#SiNS|LD movement pattern (pearson) 5dpf|b D1 distmoved 5dpf|percent scrunching Tail 12d|mean firing rate|number network spikes|percent affected 4dpf|a L1 distmoved 5dpf|LD movement pattern (spearman) 1dpf|LD movement pattern (spearman) 5dpf|e L3 distmoved 5dpf
Captan,133-06-2,1.07E-05,3.35E-05,3.177709884,0.000188015,TOX21_AR_BLA_Antagonist_viability|TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_CAR_Agonist_viabillity|TOX21_CASP3_CHO_viability|TOX21_FXR_BLA_agonist_viability|TOX21_HRE_BLA_Agonist_viability|TOX21_PGC_ERR_viability|TOX21_PPARg_BLA_antagonist_viability|TOX21_RAR_LUC_Agonist_viability|TOX21_RORg_LUC_CHO_Antagonist_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_GLO_00hr_ctrl_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability|TOX21_RT_HEPG2_GLO_40hr_viability|TOX21_SBE_BLA_Antagonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
"o,p'-DDE",3424-82-6,1.35E-05,1.92E-05,7.055562677,0.000238936,BSK_3C_Proliferation_down|BSK_3C_Vis_down|BSK_LPS_SRB_down|BSK_SAg_Proliferation_down|TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
MON-4660,71526-07-3,0,0,1.893604265,0,ACEA_ER_AUC_viability
"1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane",53-19-0,1.14E-05,0.026939292,0.004245812,0.000201724,TOX21_RT_HEK293_FLO_24hr_viability
"p,p'-DDD",72-54-8,1.29E-05,0.000118513,1.086931649,0.000227185,APR_HepG2_MitoMembPot_24h_dn|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|BURST_DURATION_AVG_ (SEC)|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
"2,2'-Dichlorobiphenyl",13029-08-8,2.40E-05,5.43E-05,4.420072006,0.000423033,TOX21_RT_HEK293_FLO_16hr_viability|TOX21_RT_HEK293_FLO_24hr_viability|TOX21_RT_HEK293_FLO_40hr_viability|TOX21_RT_HEPG2_FLO_32hr_ctrl_viability
Dieldrin,60-57-1,1.15E-05,0.159812585,0.000722657,0.000203683,SH-S5Y5 viability
Aldrin,309-00-2,1.10E-05,1.35E-05,8.170142488,0.00019389,APR_HepG2_CellLoss_24h_dn|APR_HepG2_CellLoss_72h_dn|BSK_3C_Proliferation_down|BSK_hDFCGF_Proliferation_down|BSK_hDFCGF_SRB_down|TOX21_PPARd_BLA_Agonist_viability
Isodrin,465-73-6,1.31E-05,2.99E-05,4.380451802,0.000231102,BSK_3C_SRB_down|BSK_3C_Vis_down|BSK_CASM3C_Proliferation_down|BSK_LPS_SRB_down|BSK_SAg_PBMCCytotoxicity_down|BSK_SAg_Proliferation_down|BSK_SAg_SRB_down|BSK_hDFCGF_Proliferation_down
Endrin,72-20-8,1.05E-05,0.000319321,0.330373876,0.000186056,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|BURST_DURATION_AVG_ (SEC)|NUMBER_OF_SPIKES_PER_BURST_AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|AREA_UNDER_CROSS_CORRELATION
Imazalil,35554-44-0,2.11E-06,2.45E-05,0.862786119,3.72E-05,NCCT_MITO_basal_resp_rate_OCR_dn|NVS_GPCR_gOpiateK|NVS_GPCR_hM1|NVS_GPCR_hM2|NVS_GPCR_hM3|NVS_GPCR_hM4|NVS_GPCR_hOpiate_mu|NVS_GPCR_rOpiate_NonSelective|NVS_IC_rNaCh_site2|NVS_TR_gDAT|NVS_TR_hDAT|NVS_TR_hNET|NVS_TR_rVMAT2|NVS_TR_hSERT|NVS_TR_rSERT|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NETWORK_BURST_PERCENTAGE|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Thiacloprid,111988-49-9,0,0,0.574328864,0,NVS_LGIC_hNNR_NBungSens|NVS_LGIC_rNNR_BungSens|SH-S5Y5 neurite outgrowth
Amoxapine,14028-44-5,0,0,1.341904787,0,TOX21_SSH_3T3_GLI3_Agonist_viability|TOX21_TR_LUC_GH3_Antagonist_viability
Ticlatone,70-10-0,1.11E-07,3.47E-07,3.19603357,1.96E-06,TOX21_CASP3_CHO_viability
2-Chloro-N-phenylacetamide,587-65-5,3.33E-07,3.60E-07,9.25444268,5.88E-06,ACEA_ER_AUC_viability|TOX21_CASP3_CHO_viability|TOX21_ERR_viability|TOX21_HSE_BLA_agonist_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_TR_LUC_GH3_Antagonist_viability|TOX21_VDR_BLA_Agonist_viability
"1,2-Bis(chloromethyl)benzene",612-12-4,0,0,19.86528687,0,TOX21_RORg_LUC_CHO_Antagonist_viability
"2-Chloro-N,N-bis(2-chloroethyl)ethanamine",555-77-1,1.11E-07,1.36E-06,0.818011109,1.96E-06,TOX21_HRE_BLA_Agonist_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Tris(2-chloroethyl) phosphate,115-96-8,0.000906372,0.006026811,1.503899459,0.015985178,IBI|NSDsd
Tetramethylthiuram monosulfide,97-74-5,3.55E-06,5.50E-05,0.645561909,6.27E-05,BSK_3C_Proliferation_down|BSK_3C_SRB_down|BSK_CASM3C_Proliferation_down|BSK_hDFCGF_Proliferation_down|BSK_hDFCGF_SRB_down|TOX21_ARE_BLA_agonist_viability|TOX21_AR_BLA_Antagonist_viability|TOX21_Aromatase_Inhibition_viability|TOX21_CAR_Antagonist_viability|TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability|TOX21_ERb_BLA_Agonist_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_FXR_BLA_agonist_viability|TOX21_FXR_BLA_antagonist_viability|TOX21_H2AX_HTRF_CHO_viability|TOX21_PGC_ERR_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PR_BLA_Agonist_viability|TOX21_PR_BLA_Antagonist_viability|TOX21_RORg_LUC_CHO_Antagonist_viability|TOX21_RT_HEK293_FLO_24hr_viability|TOX21_RT_HEK293_FLO_32hr_viability|TOX21_RT_HEK293_FLO_40hr_viability|TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_FLO_24hr_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_RT_HEPG2_GLO_16hr_ctrl_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability|TOX21_RT_HEPG2_GLO_40hr_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
"N,N-Dimethyl-4-nitrosoaniline",138-89-6,1.11E-07,9.32E-08,11.9115973,1.96E-06,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_CAR_Agonist_viabillity|TOX21_CAR_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_GR_BLA_Antagonist_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PPARg_BLA_antagonist_viability|TOX21_RAR_LUC_Agonist_viability|TOX21_RT_HEPG2_GLO_00hr_ctrl_viability|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_RT_HEPG2_GLO_16hr_ctrl_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_40hr_viability
"N,N-Dimethyl-p-phenylenediamine",99-98-9,0,0,14.10210113,0,TOX21_AR_BLA_Antagonist_viability|TOX21_HDAC_Inhibition_viability|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RXR_BLA_Agonist_viability
3-Dimethylaminophenol,99-07-0,0.000226204,0.126190261,0.017925651,0.00398944,TOX21_RT_HEPG2_FLO_24hr_viability
Acetamiprid,135410-20-7,1.73E-05,0.000761787,0.22740548,0.000305524,NVS_LGIC_hNNR_NBungSens|NVS_LGIC_rNNR_BungSens|SH-S5Y5 neurite outgrowth
Clothianidin,210880-92-5,2.22E-07,2.88E-06,0.769953256,3.92E-06,NVS_GPCR_rmAdra2B|NVS_LGIC_hNNR_NBungSens|SH-S5Y5 neurite outgrowth
Theophylline,58-55-9,1.44E-06,1.74E-05,0.831408553,2.55E-05,NVS_GPCR_bAdoR_NonSelective|NVS_GPCR_hAdoRA1|NVS_GPCR_hAdoRA2a
N-Methyl-2-pyrrolidone,872-50-4,0.012170833,2.10777526,0.057742556,0.214650273,SH-S5Y5 neurite outgrowth
Olanzapine,132539-06-1,0,0,1.964482766,0,TOX21_AhR_LUC_Agonist_viability|TOX21_Aromatase_Inhibition_viability|TOX21_CAR_Agonist_viabillity|TOX21_CASP3_CHO_viability|TOX21_ERR_viability|TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability|TOX21_PXR_viability|TOX21_TR_LUC_GH3_Antagonist_viability
Thiamethoxam,153719-23-4,2.78E-06,0.004016711,0.006911609,4.90E-05,SH-S5Y5 neurite outgrowth
5-Chloro-2-methyl-3(2H)-isothiazolone,26172-55-4,0.000166683,0.003181686,0.523881525,0.00293969,MFR|BR|ISI|%SiB|BD|IBI|#AE|#ABE|#NS|NSD|%SiNS|NS-ISI|NSDsd|#SiNS|r|MI
Aldoxycarb,1646-88-4,2.78E-06,1.42E-05,1.96155317,4.90E-05,ACEA_AR_antagonist_AUC_viability
Propoxur,114-26-1,0,0,1.584383487,0,NVS_ENZ_hAChE|NVS_ENZ_rAChE
Carbofuran,1563-66-2,0.000475951,0.055806403,0.085286028,0.008394079,NVS_ENZ_hAChE|NVS_ENZ_rAChE
3-Hydroxycarbofuran,16655-82-6,1.11E-07,0.010612715,0.000104637,1.96E-06,SH-S5Y5 neurite outgrowth
Oxamyl,23135-22-0,2.78E-06,1.03E-05,2.704492303,4.90E-05,APR_HepG2_MitoMass_72h_up|NVS_ENZ_hAChE|NVS_ENZ_rAChE
Aldicarb,116-06-3,2.89E-06,2.09E-05,1.381011469,5.09E-05,APR_HepG2_MitoMembPot_72h_dn|NVS_ENZ_rAChE|#SiNS|r|percent affected 4dpf|LD movement pattern (pearson) 5dpf|LD movement pattern (spearman) 4dpf|mean correlation|a L1 distmoved 4dpf|b D1 distmoved 4dpf|number network spikes|b D1 distmoved 5dpf|percent affected 4dpf|LD movement pattern (spearman) 5dpf
"1,1,3-Trimethyl-2-thiourea",2489-77-2,5.55E-07,1.43E-06,3.893326281,9.79E-06,TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
N-Methyl-4-nitroaniline,100-15-2,0,0,13.1974008,0,TOX21_CAR_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_CASP3_HEPG2_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_PGC_ERR_viability|TOX21_SSH_3T3_GLI3_Agonist_viability
(N-6)-Methyladenine,443-72-1,3.34E-05,0.000796856,0.419465648,0.000589505,TOX21_MMP_ratio_down
Dimethyl isophthalate,1459-93-4,0,0,2.874491399,0,TOX21_RT_HEK293_FLO_24hr_viability|TOX21_RT_HEPG2_FLO_00hr_ctrl_viability
Methylparaben,99-76-3,0,0,2.241652934,0,ACEA_AR_antagonist_AUC_viability
"Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate",1458-18-0,0.00016113,0.003474741,0.463718887,0.002841766,TOX21_CASP3_CHO_viability|TOX21_PPARd_BLA_antagonist_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability
Cyclobendazole,31431-43-3,2.22E-07,1.04E-05,0.213656505,3.92E-06,TOX21_CASP3_CHO_viability|TOX21_PGC_ERR_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
2-Methoxy-4-vinylphenol,7786-61-0,2.22E-07,6.15E-07,3.612895494,3.92E-06,NVS_TR_hNET
Eugenol,97-53-0,3.33E-07,0.00011515,0.028931345,5.88E-06,BURST_PERCENTAGE_AVG_(SEC)|NETWORK_BURST_PERCENTAGE|SYNCHRONY_INDEX
2-Methoxy-4-nitroaniline,97-52-9,0,0,1.135815767,0,ACEA_AR_agonist_AUC_viability|ACEA_AR_antagonist_AUC_viability|NCCT_HEK293T_CellTiterGLO|TOX21_CAR_Agonist_viabillity
"3,3'-Dimethoxybenzidine",119-90-4,0.000399328,0.000651043,6.133660563,0.007042722,NVS_GPCR_r5HT1_NonSelective
Epirizole,18694-40-1,1.11E-07,1.66E-07,6.675590265,1.96E-06,TOX21_PR_BLA_Agonist_viability
"4'-Chloro-2',5'-dimethoxyacetoacetanilide",4433-79-8,1.11E-07,6.92E-07,1.604200854,1.96E-06,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_p53_BLA_p4_viability
(E)-Anethole,4180-23-8,0,0,0.275208464,0,NUMBER_OF_SPIKES|NUMBER_OF_SPIKES_PER_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION
Chlorotrianisene,569-57-3,4.82E-05,7.52E-05,6.405524105,0.000849984,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability
4-Methoxyaniline,104-94-9,2.22E-07,2.93E-07,7.579181195,3.92E-06,TOX21_ERR_viability
6-Methoxy-2-benzothiazolamine,1747-60-0,3.33E-07,9.42E-06,0.353629681,5.88E-06,TOX21_RT_HEK293_GLO_32hr_viability
Brucine,357-57-3,4.44E-06,5.23E-06,8.489505243,7.83E-05,TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
UK-333747,197077-55-7,0,0,2.09104935,0,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Fluvoxamine,54739-18-3,0,0,2.507305743,0,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability
Ethylene glycol dimethyl ether,110-71-4,3.11E-06,8.28E-05,0.375430056,5.48E-05,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Dicrotophos,141-66-2,0.000199331,0.000667936,2.984276523,0.003515486,NVS_ENZ_hES
Difenzoquat metilsulfate,43222-48-6,1.69E-05,0.000150053,1.124889405,0.00029769,NCCT_MITO_max_resp_rate_OCR_dn|NVS_ENZ_hES|NVS_GPCR_gOpiateK|NVS_GPCR_hAdra2A|NVS_GPCR_hAdra2C|NVS_GPCR_hM1|NVS_GPCR_hM2|NVS_GPCR_hM3|NVS_GPCR_hM4|NVS_GPCR_rAdra1A|NVS_GPCR_rAdra1B|NVS_GPCR_rAdra1_NonSelective|NVS_GPCR_rAdra2_NonSelective|NVS_GPCR_rmAdra2B|NVS_IC_rNaCh_site2|NVS_TR_hNET|NVS_GPCR_g5HT4|NVS_GPCR_h5HT7|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|BURST_DURATION_AVG_ (SEC)|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Piragliatin,625114-41-2,3.33E-07,7.67E-07,4.342231722,5.88E-06,APR_HepG2_MitoMass_72h_up
4-Chlorophenyl methyl sulfone,98-57-7,2.52E-05,0.451449036,0.000558376,0.000444577,TOX21_RT_HEPG2_FLO_16hr_ctrl_viability
3-Methyl-4-(methylthio)phenol,3120-74-9,1.33E-06,2.98E-06,4.478637977,2.35E-05,NVS_ENZ_rMAOAC|NVS_TR_gDAT
Metribuzin,21087-64-9,2.22E-07,9.77E-07,2.274309757,3.92E-06,ACEA_AR_agonist_AUC_viability
1-Hexyl-3-methylimidazolium tetrafluoroborate,244193-50-8,7.80E-05,0.000142397,5.474511189,0.001374858,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_CAR_Antagonist_viability|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability
1-Hexyl-3-methylimidazolium hexafluorophosphate,304680-35-1,0,0,1.228309783,0,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_CAR_Agonist_viabillity|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
1-Ethyl-3-methylimidazolium hexafluorophosphate,155371-19-0,6.66E-07,0.000127218,0.052373449,1.18E-05,TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_GLO_16hr_ctrl_viability
Tralopyril,122454-29-9,1.59E-05,0.00057066,0.278271329,0.000280064,ACEA_ER_AUC_viability|BSK_3C_Vis_down|BSK_CASM3C_Proliferation_down|BSK_SAg_Proliferation_down|TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_CAR_Agonist_viabillity|TOX21_CASP3_CHO_viability|TOX21_ERR_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability|TOX21_SBE_BLA_Agonist_viability|TOX21_SBE_BLA_Antagonist_viability
Tetraconazole,112281-77-3,1.12E-05,6.25E-05,1.794879691,0.000197807,NCCT_MITO_basal_resp_rate_OCR_dn|NCCT_MITO_max_resp_rate_OCR_dn|NVS_IC_rCaBTZCHL|NVS_IC_rCaDHPRCh_L|NVS_TR_hDAT
Diflubenzuron,35367-38-5,2.11E-06,1.05E-05,2.014236997,3.72E-05,TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
2-(Thiocyanomethylthio)benzothiazole,21564-17-0,3.31E-05,0.000141477,2.339046788,0.000583629,APR_HepG2_MitoMass_1h_dn|NCCT_MITO_basal_resp_rate_OCR_dn|NCCT_MITO_max_resp_rate_OCR_dn|NVS_GPCR_hAdra2A|NVS_GPCR_hDRD1|NVS_TR_hNET|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
"1,3-Diphenylguanidine",102-06-7,1.45E-05,0.000288675,0.503932586,0.000256562,NVS_GPCR_hM4|NVS_GPCR_rAdra1A|NVS_GPCR_rmAdra2B|NVS_GPCR_h5HT7|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|AREA_UNDER_CROSS_CORRELATION|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION
"1,3-Diiminobenz(f)isoindoline",65558-69-2,4.44E-07,3.68E-06,1.207719087,7.83E-06,TOX21_MMP_ratio_down|TOX21_MMP_rhodamine
Indole,120-72-9,1.89E-06,1.69E-05,1.113993985,3.33E-05,TOX21_RT_HEPG2_FLO_32hr_ctrl_viability
Phenothiazine,92-84-2,7.22E-06,3.59E-05,2.008601723,0.000127302,NVS_ENZ_rMAOAC|TOX21_MMP_rhodamine|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|NETWORK_BURST_PERCENTAGE|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
Guanabenz,5051-62-7,1.22E-06,1.03E-05,1.180448485,2.15E-05,TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability|TOX21_SSH_3T3_GLI3_Agonist_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
6-Aminonicotinamide,329-89-5,5.17E-05,0.000742251,0.697179502,0.000912655,CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss|CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss|MFR|BR|ISI|%SiB|BD|IBI|#AE|#ABE|#NS|NSP|NSD|%SiNS|NS-ISI|NSDsd|#SiNS|r|MI
2-Benzimidazolylurea,24370-25-0,3.30E-05,4.05E-11,8142077.251,0.000581671,TOX21_RT_HEK293_FLO_08hr_viability|TOX21_RT_HEK293_FLO_16hr_viability
"2-Bromo-4,6-dinitroaniline",1817-73-8,2.41E-05,3.26E-05,7.388125608,0.000424992,TOX21_SSH_3T3_GLI3_Antagonist_viability
"4-Nitro-1,2-phenylenediamine",99-56-9,1.11E-07,1.49E-07,7.449603661,1.96E-06,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_Aromatase_Inhibition_viability|TOX21_CASP3_CHO_viability|TOX21_PXR_viability|TOX21_SSH_3T3_GLI3_Agonist_viability
"4-Chloro-1,2-diaminobenzene",95-83-0,0,0,3.881279347,0,TOX21_RT_HEPG2_FLO_40hr_ctrl_viability
2-Amino-5-nitrophenol,121-88-0,0,0,2.020884065,0,BSK_hDFCGF_Proliferation_down
2-Amino-4-nitrophenol,99-57-0,0,0,11.08188207,0,TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability|TOX21_CAR_Antagonist_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_PXR_viability|TOX21_RT_HEK293_GLO_08hr_viability
3-(Trifluoromethyl)aniline,98-16-8,4.05E-05,4.88E-05,8.310241868,0.000714848,TOX21_RT_HEK293_FLO_24hr_viability
"3,4-Dichloroaniline",95-76-1,0,0,1.195086944,0,ACEA_AR_agonist_AUC_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
2-Amino-4-chlorophenol,95-85-2,0,0,1.767044562,0,TOX21_MMP_ratio_down
"4-Chloro-1,3-diaminobenzene",5131-60-2,1.11E-07,6.17E-07,1.799971931,1.96E-06,TOX21_VDR_BLA_Agonist_viability
"1,3-Benzenediamine",108-45-2,1.83E-05,0.000110738,1.654622266,0.000323151,NCCT_MITO_inhib_resp_rate_OCR_up|NVS_ENZ_rMAOAC
"4-Nitro-1,3-benzenediamine",5131-58-8,0,0,7.355652811,0,TOX21_Aromatase_Inhibition_viability|TOX21_PXR_viability
4-Nitroaniline,100-01-6,1.11E-07,3.01E-07,3.685848185,1.96E-06,ACEA_AR_antagonist_AUC_viability|TOX21_ERR_viability
C.I. Azoic Diazo Component 112,92-87-5,7.77E-07,2.59E-06,3.003739934,1.37E-05,NVS_TR_gDAT|NVS_TR_hNET|NVS_TR_rNET
4-Biphenylamine,92-67-1,0,0,1.36230143,0,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Dapsone,80-08-0,1.25E-05,0.00035006,0.358463624,0.000221309,NVS_TR_gDAT|NVS_TR_hDAT|NVS_GPCR_h5HT6
"4,4'-Diaminobiphenyl methane",101-77-9,9.88E-06,9.74E-05,1.014858052,0.000174305,NVS_TR_hDAT
4-Chloroaniline,106-47-8,0.000369012,0.004002552,0.921940909,0.006508055,ACEA_AR_agonist_AUC_viability|ACEA_AR_antagonist_AUC_viability|ACEA_ER_AUC_viability|BSK_hDFCGF_Proliferation_down
"1,4-Diaminoanthraquinone",128-95-0,0.000203328,0.551300295,0.003688161,0.003585991,TOX21_MMP_ratio_down|TOX21_MMP_rhodamine
"N-Phenyl-1,4-benzenediamine",101-54-2,0,0,3.989564811,0,TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability|TOX21_PGC_ERR_viability|TOX21_TR_LUC_GH3_Antagonist_viability
4-Aminophenol,123-30-8,1.11E-07,8.44E-08,13.1569178,1.96E-06,TOX21_CAR_Agonist_viabillity|TOX21_CAR_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_PGC_ERR_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_p53_BLA_p5_viability
"4,4'-Oxydianiline",101-80-4,0.000956343,0.073090712,0.130843329,0.016866498,NVS_TR_gDAT|NVS_TR_hDAT
2-Aminodiphenylamine,534-85-0,0,0,3.322363509,0,TOX21_CASP3_HEPG2_viability|TOX21_ERR_viability|TOX21_PGC_ERR_viability|TOX21_RT_HEK293_GLO_08hr_viability|TOX21_TR_LUC_GH3_Antagonist_viability
1-Naphthylamine,134-32-7,1.11E-07,5.95E-07,1.86757466,1.96E-06,BSK_3C_Proliferation_down
2-Naphthylamine,91-59-8,1.11E-07,2.57E-06,0.431950301,1.96E-06,APR_HepG2_MitoMass_72h_up|APR_HepG2_MitoMembPot_24h_dn|NVS_TR_hNET|NUMBER_OF_SPIKES_PER_BURST_AVG|INTER_BURST_INTERVAL_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG
"6-Phenyl-1,3,5-triazine-2,4-diamine",91-76-9,2.22E-06,9.97E-05,0.222772934,3.92E-05,NVS_GPCR_hAdoRA1|NVS_GPCR_hAdoRA2a
2-Amino-5-nitrothiazole,121-66-4,5.55E-07,5.65E-07,9.825872729,9.79E-06,TOX21_AhR_LUC_Agonist_viability|TOX21_Aromatase_Inhibition_viability|TOX21_CAR_Agonist_viabillity
"4,4'-Diaminodicyclohexylmethane",1761-71-3,9.99E-07,1.95E-06,5.129541007,1.76E-05,TOX21_PR_BLA_Agonist_viability
Praziquantel,55268-74-1,0,0,15.16963902,0,TOX21_SSH_3T3_GLI3_Antagonist_viability
Thidiazuron,51707-55-2,1.19E-05,0.00015528,0.765203287,0.000209558,APR_HepG2_MitoMembPot_1h_dn|NVS_LGIC_bGABARa5|NVS_LGIC_rGABARa6|TOX21_MMP_ratio_down|NVS_GPCR_h5HT5A
"Bis(2,3-epoxypropyl) cyclohexane-1,2-dicarboxylate",5493-45-8,0,0,5.198402237,0,TOX21_RT_HEK293_GLO_32hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Caprolactam,105-60-2,0.004305321,0.009707478,4.435056303,0.075930576,TOX21_CAR_Antagonist_viability|TOX21_PR_BLA_Antagonist_viability
"1,1'-Disulfanediyldiazepan-2-one",23847-08-7,4.44E-07,2.73E-07,16.24311363,7.83E-06,TOX21_CASP3_CHO_viability|TOX21_RT_HEK293_FLO_32hr_viability|TOX21_SSH_3T3_GLI3_Antagonist_viability
1-Phenyl-3-pyrazolidinone,92-43-3,1.11E-07,1.92E-07,5.789446571,1.96E-06,TOX21_ERb_BLA_Antagonist_viability
"cis-1,2,3,6-Tetrahydrophthalimide",1469-48-3,3.33E-07,7.69E-07,4.332004189,5.88E-06,TOX21_PR_BLA_Antagonist_viability
"5,5-Diphenylhydantoin",57-41-0,0,0,1.424980997,0,NVS_TR_hDAT|BD
Thiouracil,141-90-2,2.67E-05,0.000113684,2.344349392,0.000470037,MFR|BR|%SiB|BD|IBI|#AE|#ABE|#NS|NSP|NSD|%SiNS|NS-ISI|NSDsd|#SiNS|r|MI
N-Nitrosomorpholine,59-89-2,0.000406546,0.009759434,0.416566974,0.007170024,TOX21_RT_HEK293_GLO_08hr_viability|TOX21_RT_HEK293_GLO_16hr_viability|TOX21_RT_HEK293_GLO_24hr_viability|TOX21_RT_HEK293_GLO_40hr_viability
Triphenylphosphine oxide,791-28-6,6.22E-06,3.53E-05,1.760434151,0.000109675,NVS_GPCR_gOpiateK
Chlorpheniramine maleate,113-92-8,1.55E-06,1.07E-05,1.44785506,2.74E-05,NVS_ENZ_hES|NVS_GPCR_hDRD1|NVS_GPCR_hM2|NVS_IC_rNaCh_site2|NVS_TR_gDAT|NVS_TR_hDAT|NVS_TR_hNET
Perfluorooctanoic acid,335-67-1,0.000507377,0.000580044,8.74721608,0.008948331,TOX21_ERb_BLA_Agonist_viability|TOX21_HRE_BLA_Agonist_viability
Perfluoroheptanoic acid,375-85-9,2.17E-05,5.75E-05,3.764509197,0.000381905,APR_HepG2_MitoMass_72h_dn
4-Nitrobenzoic acid,62-23-7,1.11E-07,3.87E-06,0.286937404,1.96E-06,NVS_LGIC_rGABAR_NonSelective
"2,4-Dichlorophenoxybutyric acid",94-82-6,9.55E-06,3.95E-05,2.414752276,0.00016843,NCCT_MITO_basal_resp_rate_OCR_dn|NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|INTER_BURST_INTERVAL_AVG_(SEC)|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG
4-Chlorophenoxyacetic acid,122-88-3,2.22E-06,0.000249384,0.089057563,3.92E-05,ACEA_AR_antagonist_AUC_viability
"2-(1-Chlorocyclopropyl)-1-(2-chlorophenyl)-3-(1H-1,2,4-triazol-1-yl)-2-propanol",120983-64-4,0,0,6.473645691,0,BSK_3C_Proliferation_down|TOX21_RT_HEPG2_GLO_08hr_ctrl_viability|TOX21_RT_HEPG2_GLO_16hr_ctrl_viability
Prothioconazole,178928-70-6,0,0,5.80184226,0,BSK_3C_Proliferation_down|BSK_3C_SRB_down|BSK_4H_SRB_down|BSK_CASM3C_SRB_down|BSK_SAg_Proliferation_down|BSK_hDFCGF_Proliferation_down
2-Hydroxy-3-phenoxypropyl prop-2-enoate,16969-10-1,0,0,0.141140534,0,TOX21_RT_HEPG2_GLO_08hr_ctrl_viability
2-Phenylphenol,90-43-7,0.003682343,5.582141747,0.00659665,0.064943458,SH-S5Y5 viability
"4,4'-Sulfonylbis[2-(prop-2-en-1-yl)phenol]",41481-66-7,6.36E-05,0.000339596,1.873705974,0.001122214,APR_HepG2_MitoMass_24h_dn|NCCT_MITO_basal_resp_rate_OCR_dn|NCCT_MITO_max_resp_rate_OCR_dn|NVS_GPCR_bAdoR_NonSelective|NVS_GPCR_hAdoRA1|NVS_GPCR_hAdoRA2a|NVS_GPCR_hOpiate_mu|NVS_GPCR_rOpiate_NonSelectiveNa|NVS_IC_rCaDHPRCh_L|NVS_TR_gDAT|NVS_TR_hNET|NVS_GPCR_g5HT4|NUMBER_OF_SPIKES_PER_BURST_AVG|BURST_PERCENTAGE_AVG_(SEC)|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ AVG|NUMBER_OF_SPIKES_PER_NETWORK_BURST_ STD|NUMBER_OF_ELECS_PARTICIPATING_IN_BURST_AVG|AREA_UNDER_CROSS_CORRELATION
"2,3,4,6-Tetrachlorophenol",58-90-2,2.34E-05,3.73E-05,6.289488335,0.000413241,BSK_3C_Proliferation_down|BSK_3C_SRB_down|BSK_3C_Vis_down|BSK_4H_SRB_down|BSK_LPS_SRB_down|BSK_SAg_Proliferation_down|BSK_SAg_SRB_down|BSK_hDFCGF_Proliferation_down
"((3,4-Dihydroxyphenyl)methylene)-Propanedinitrile",118409-57-7,0,0,6.212609841,0,TOX21_MMP_rhodamine
Quinalizarin,81-61-8,4.59E-05,6.60E-05,6.952173498,0.000808855,BSK_3C_SRB_down
Clioquinol,130-26-7,2.38E-05,7.97E-05,2.983082655,0.000419116,TOX21_AR_BLA_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_PPARg_BLA_antagonist_viability
"4,6-Dichloro-1,3-benzenediol",137-19-9,0,0,2.704758548,0,TOX21_MMP_ratio_down|TOX21_MMP_rhodamine
4-Nitrophenol,100-02-7,0,0,16.75875312,0,TOX21_ERR_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_PGC_ERR_viability|TOX21_SSH_3T3_GLI3_Agonist_viability
Nitroxoline,4008-48-4,0,0,1.90648262,0,TOX21_AR_BLA_Antagonist_viability|TOX21_CASP3_CHO_viability|TOX21_ERR_viability|TOX21_PPARd_BLA_Agonist_viability|TOX21_PXR_viability|TOX21_RT_HEPG2_GLO_24hr_ctrl_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability|TOX21_RT_HEPG2_GLO_40hr_viability|TOX21_RXR_BLA_Agonist_viability
Cloxyquin,130-16-5,2.30E-05,6.54E-05,3.515285288,0.000405407,TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability|TOX21_ERb_BLA_Antagonist_viability|TOX21_PR_BLA_Antagonist_viability|TOX21_PXR_viability
Hydroquinone,123-31-9,6.92E-05,0.013236974,0.052264774,0.001220138,NUMBER_OF_SPIKES|MEAN_FIRING_RATE_HZ|NUMBER_OF_BURSTS|NUMBER_OF_SPIKES_PER_BURST_AVG|AREA_UNDER_CROSS_CORRELATION
C.I. Solvent Yellow 14,842-07-9,0.002178757,0.007018072,3.104495041,0.038425532,ATG_FoxA2_CIS_up|BSK_SAg_Proliferation_down|NCCT_HEK293T_CellTiterGLO|TOX21_Aromatase_Inhibition_viability|TOX21_CAR_Agonist_viabillity|TOX21_ERR_viability|TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability|TOX21_PGC_ERR_viability|TOX21_PXR_viability
1-Naphthol,90-15-3,5.11E-06,1.19E-05,4.307435603,9.01E-05,NVS_ENZ_rMAOAC|TOX21_MMP_fitc
2-Naphthalenol,135-19-3,0.000538359,0.00328686,1.63791422,0.009494749,NVS_ENZ_rMAOAC|NVS_ENZ_rMAOAP|NVS_ENZ_rMAOBC|NVS_TR_hNET|NVS_TR_rNET|NVS_GPCR_p5HT2C
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone,77439-76-0,2.22E-07,7.45E-06,0.298302257,3.92E-06,TOX21_AR_BLA_Antagonist_viability|TOX21_RT_HEPG2_GLO_32hr_ctrl_viability
Bronopol,52-51-7,5.19E-05,0.000267088,1.941654953,0.000914614,APR_HepG2_MitoMembPot_24h_dn|NVS_GPCR_bAdoR_NonSelective|NVS_GPCR_rOpiate_NonSelective|NUMBER_OF_SPIKES|NUMBER_OF_BURSTS|BURST_DURATION_AVG_ (SEC)|BURST_PERCENTAGE_AVG_(SEC)|BURST_PERCENTAGE_STD_(SEC)|FULL_WIDTH_AT_HALF_HEIGHT_OF_CROSS_CORRELATION|SYNCHRONY_INDEX
1-Hydroxybenzotriazole,2592-95-2,8.00E-06,0.004435752,0.018024987,0.000141011,TOX21_AR_BLA_Antagonist_viability|TOX21_ERb_BLA_Agonist_viability|TOX21_ERb_BLA_Antagonist_viability
CP-544439,230954-09-3,0,0,12.1460602,0,NCCT_MITO_basal_resp_rate_OCR_dn|NCCT_MITO_max_resp_rate_OCR_dn
6-Mercaptopurine,50-44-2,1.33E-06,2.90E-05,0.459892851,2.35E-05,TOX21_CAR_Agonist_viabillity|TOX21_ERR_viability|TOX21_PGC_ERR_viability|TOX21_PR_BLA_Agonist_viability|TOX21_PXR_viability|TOX21_SBE_BLA_Agonist_viability|TOX21_SBE_BLA_Antagonist_viability|TOX21_VDR_BLA_antagonist_viability|TOX21_p53_BLA_p2_viability|TOX21_p53_BLA_p4_viability
2-Mercaptobenzimidazole,583-39-1,5.66E-06,4.42E-06,12.80168947,9.99E-05,TOX21_PR_BLA_Antagonist_viability
Benzothiazole,95-16-9,0,0,0.01342077,0,SH-S5Y5 neurite outgrowth
2-Mercaptobenzothiazole,149-30-4,0,0,14.20762084,0,APR_HepG2_MitoMembPot_24h_dn|APR_HepG2_MitoMembPot_72h_dn|NVS_TR_hNET
